Indaptus Therapeutics, Inc.
INDP
$0.2701
-$0.0589-17.90%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -25.10% | -21.14% | -17.10% | 18.87% | -8.67% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.96% | -0.19% | -26.04% | 17.56% | -11.49% |
| Operating Income | -15.96% | 0.19% | 26.04% | -17.56% | 11.49% |
| Income Before Tax | -19.06% | -3.20% | 21.76% | -23.73% | 10.50% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -19.06% | -3.20% | 21.76% | -23.73% | 10.50% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.06% | -3.20% | 21.76% | -23.73% | 10.50% |
| EBIT | -15.96% | 0.19% | 26.04% | -17.56% | 11.49% |
| EBITDA | -15.98% | 0.18% | 26.04% | -17.57% | 11.50% |
| EPS Basic | 28.72% | 20.65% | 30.88% | -21.67% | 10.94% |
| Normalized Basic EPS | 28.71% | 20.65% | 30.88% | -21.67% | 10.94% |
| EPS Diluted | 28.72% | 20.65% | 30.88% | -21.67% | 10.94% |
| Normalized Diluted EPS | 28.71% | 20.65% | 30.88% | -21.67% | 10.94% |
| Average Basic Shares Outstanding | 67.04% | 30.04% | 13.21% | 1.70% | 0.49% |
| Average Diluted Shares Outstanding | 67.04% | 30.04% | 13.21% | 1.70% | 0.49% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |